Crossmark

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects

Crossref DOI link: https://doi.org/10.1007/s40261-021-01078-7

Published Online: 2021-09-21

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Knöchel, Jane https://orcid.org/0000-0001-9839-2433
Nelander, Karin

Heijer, Maria

Lindstedt, Eva-Lotte

Forsberg, Gun-Britt

Whatling, Carl

Shimada, Hitoshi

Han, David S.

Gabrielsen, Anders

Garkaviy, Pavlo

Ericsson, Hans
License Information

Text and Data Mining valid from 2021-09-21

Version of Record valid from 2021-09-21
More Information

Article History

Accepted: 31 August 2021

First Online: 21 September 2021

Declarations

:

: AstraZeneca provided funding to PAREXEL for the conduct of this study.

: J.K, K.N, M.H, E.-L.L,G.-B.F, C.W, H.S, A.G, P.G, and H.E are all employees of AstraZeneca. D.H. is employed by Parexel.

: The study was approved by Aspire Institutional Review Board and was conducted in accordance with the Declaration of Helsinki following Good Clinical Practice Guidelines.

: Study participants provided written informed consent.

: Not applicable.

: The authors confirm that all relevant data supporting the findings are included in this article and/or its supplementary information file.

: Not applicable.

Document is current

Any future updates will be listed below